Improving Access to Healthcare Improving Access to Healthcare According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Spotlight on GPP Spotlight on GPP Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Embracing diversity in clinical trials Embracing diversity in clinical trials At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Are combination therapies the answer to battling KRAS cancers? Are combination therapies the answer to battling KRAS cancers? Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Chronic kidney disease in cats Chronic kidney disease in cats Detect and manage chronic kidney disease and high blood pressure in cats
1990-2023: Value through Innovation 1990-2023: Value through Innovation The Boehringer Ingelheim history from 1990 to 2023, with milestones
Collaboration to fight NCDs Collaboration to fight NCDs 70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
We support non-linear career paths. We support non-linear career paths. Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Europe needs a vibrant research eco-system Europe needs a vibrant research eco-system At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
cat dog flea allergy dermatitis cat dog flea allergy dermatitis Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Clinical trials deliver medical breakthroughs – but how do they happen? Clinical trials deliver medical breakthroughs – but how do they happen? Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Catherine Alonzo Catherine Alonzo Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.
Digital solution for individualized diabetes care Digital solution for individualized diabetes care With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.
Heart Failure in Women Heart Failure in Women Experts discuss disparities in heart failure care and management for women
10 things you should know about rabies 10 things you should know about rabies 10 things you should know about rabies
Mental health: a $1 trillion burden demanding policy action Mental health: a $1 trillion burden demanding policy action Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
T-cell engagers: Reawakening T-cells to fight cancer T-cell engagers: Reawakening T-cells to fight cancer Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Respiratory Diseases Respiratory Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
1948-1990: Going global 1948-1990: Going global The Boehringer Ingelheim history from 1948-1990, with milestones